Search Results

We hope you find what you’re looking for. You can email us if you need additional help.

Shareholder Update: May 4, 2023

Dear Valued Shareholders, This is the news you’ve been waiting for. Optimi Health today announced that it has entered into a $1.2 million CAD definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research

Read More »

A Message For Our Shareholders

Yesterday, Optimi Health announced an important MDMA and psilocybin supply agreement for Australians approved under the country’s Authorised Prescribers Scheme. Our new long-term relationship with Mind Medicine Australia positions Optimi as the primary supplier to Australia’s newly regulated psychedelic market.

Read More »

Products do not contain psilocybin

Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.